Taplmmune, Inc. (TPIM.OB) is a developer of new innovative therapeutics and vaccines in the oncology and infectious disease areas. The company’s therapeutics and vaccines are based on technologies that utilize transporters associated with Antigen Processing (TAP). TAP therapy offers improvements in efficacy as well as reduced side effects and a boost in body defenses.

Teplmmune’s TAP cancer vaccine primarily moves antigens to the surface of cells and restores TAP proteins and the immune system’s ability to recognize and destroy cancer cells. The TAP molecule has also shown abilities to enhance the potency of vaccines against infectious diseases.

Taplmmune’s TAP has already been through clinical studies and has proven several forms of cancer that are deficient to the vaccine. Some cancers deficient to the vaccine include melanoma, colon, cervical, lung, prostate, breast and ovarian. The company began their preclinical testing of TAP in 2007, and is currently

TapImmune, Inc. (OTCBB: TPIM) announced that their TAP incorporated vaccine for the treatment of cancer was recently reviewed by a third party research article in the Journal of Investigative Dermatology, which confirmed that the company’s vaccine should be considered as a therapy for cancer.

The article, entitled, “Restoration of the Expression of Transporters Associate with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity,” was published in advance online on April 3, 2008. TapImmune is a biotechnology company that specializes in the development of immunotherapeutics for cancer and vaccines for infectious diseases, and the company’s stock rose 37.10% in Monday’s trading.

The company’s promising TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, which stands for Transporters with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without